In vivo and in vitro evaluations of functionalized mesoporous silica
The mobile crystalline material-41 (MCM-41) has been used in various fields, such as measuring cations, dye removal, and drug delivery. Modification of MCM-41 improves some properties of mesoporous materials, including surface area, adsorption capacity, thermal stability, and mechanical stability. C...
Gespeichert in:
Veröffentlicht in: | Chemical papers 2024-10, Vol.78 (15), p.8261-8270 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The mobile crystalline material-41 (MCM-41) has been used in various fields, such as measuring cations, dye removal, and drug delivery. Modification of MCM-41 improves some properties of mesoporous materials, including surface area, adsorption capacity, thermal stability, and mechanical stability. Considering of these, after synthesize of MCM-41@SiO
2
-NH-pydc, in vivo and in vitro studies of MCM-41@SiO
2
-NH-pydc were conducted. For in vitro toxicity, various concentrations of 75, 150, and 300 mg L
−1
were used in
Allium cepa
test to study the toxicity and genotoxicity of mesoporous. For in vivo toxicity, 40 Wistar albino rats were collected and acute toxicity was estimated through oral administration (PO). For the sub-chronic study, four groups of Wistar rats were randomly selected and received MCM-41@SiO
2
-NH-pydc daily by gavage at dosages of 12.5, 25, and 50 mg kg
−1
for 28 days. For hematological and biochemical tests, blood was collected, and the liver and kidney were dissected and prepared as slides to study histopathology. The lethal dose 50 (LD
50
) of MCM-41@SiO
2
-NH-pydc was found to be more than 250 mg kg
−1
. All hematological and biochemical parameters were reported as normal, indicating no serious toxicity. Therefore, based on the findings obtained, it is suggested to use MCM-41@SiO
2
-NH-pydc as a safe, appropriate, and novel carrier for drug delivery investigations. |
---|---|
ISSN: | 0366-6352 2585-7290 1336-9075 |
DOI: | 10.1007/s11696-024-03665-2 |